Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Adaptive Biotechnologies Prices Public Offering of Stock

Adaptive Biotechnologies Prices Public Offering of Stock

Jan 24, 2020
|
staff reporter

NEW YORK – Immune cell sequencing firm Adaptive Biotechnologies said after the close of the market on Thursday that it is selling 8 million shares of common stock at $26.50 per share.

The firm is selling the shares on behalf of certain investors and will not receive any proceeds from the sale.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

To Keep Up

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

On the Rise in the City

The New York Times reports that a new viral variant of concern has been identified in New York City.

Nature Studies Present Single-Cell Map of Cell Cycle, Approach Identifies Cancer Treatment Resistance Pathways, More

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

COVAX's First Shipment

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

What's Popular?

In Business News

  1. Luminex Shares Surge on Rumor of Acquisition by DiaSorin

  2. 10x Genomics Acquires Denmark's Tetramer Shop

  3. Miroculus Raises $45M in Extended Series B Financing

  4. Guardant Health Q4 Revenues Up 25 Percent

  5. Oncocyte Closes Second and Final Investment in Razor Genomics Acquisition

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.